| Project/Area Number |
14370248
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Pediatrics
|
|---|
| Research Institution | Saga University |
|---|
Principal Investigator |
ISHII Eiichi Saga University, Faculty of Medicine, Pediatrics, Professor, 医学部, 助教授 (20176126)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OHGA Shinsaku Kyushu University, Faculty of Medicine, Pediatrics, Assistant Professor, 医学部附属病院, 講師 (60233053)
YASUKAWA Masaki Ehime University, Internal Medicine, Associate Professor, 医学部, 助教授 (60127917)
YAMAMOTO Ken Kyushu University, Molecular Genetics, Associate Professor, 生体防御医学研究所, 助教授 (60274528)
SASAZUKI Takehiko International Medical Center of Japan, Research Institute, Director, 研究所長 (50014121)
IMASHUKU Shinsaku Kyoto City Institute of Health and Environmental Science, Director, 所長
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥13,300,000 (Direct Cost: ¥13,300,000)
Fiscal Year 2003: ¥5,000,000 (Direct Cost: ¥5,000,000)
Fiscal Year 2002: ¥8,300,000 (Direct Cost: ¥8,300,000)
|
|---|
| Keywords | Familial hemophagocytic lymphohistiocytosis / Performn gene / MUNC13-4 gen / NK activity / Cytotoxicity of Tlymphocytes / Linkage analysis / 遺伝子導入 / 細胞障害活性 / マイクロサテライトマーカー / 原発性血球貪食症候群 / マウスモデル |
|---|
| Research Abstract |
Familial hemophagocytic lymphohistiocytosis (FHL) is an autosomal recessive disorder occurring in infancy. In our study, clonal proliferation of T lymphocytes has been observed in FHL patients and also various organs of scid mice Cytotoxicity of these T lymphocytes for target cells is usually impaired, consequently, it may be hypothesized that T lymphocytes with cytotoxic defects for target cells will accumulate, proliferate and acquire clonality in FHL. In 1999, perforin gene (PRF1) mutation was identified as a cause of FHL2 subtype. In Japan, the incidence of FHL2 can be calculated as 20-30% of all FHL cases. Furthermore, in 2003, MUNC13-4 mutations were identified in some non-FHL2 patients (FHL3 subtype). We identified several new mutations of MUNC13-4 in FHL, and the incidence of this mutaions was approximately 30% of FHL cases. The difference of phenotypic findings can be observed between FHL2 and FHL3 subtypes. Identification of other genes responsible for remaining cases is therefore a major concern. Althogh it is considered that hematopoietic stem cell transplantation is an only accepted curative therapy for FHL, appropriate diagnosis and decision of appropriate treatment is necessary for FHL patients. In the near future, an entire pathogenesis should be clarified in order to establish appropriate therapies including immunotherapy, stem cell transplantation and gene therapy.
|
